Defence Therapeutics Inc. (DTCFF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 477.74 Thousand CAD | -86.48% |
| 2023 | 3.53 Million CAD | 390.88% |
| 2022 | 719.66 Thousand CAD | -87.17% |
| 2021 | 5.6 Million CAD | 193.38% |
| 2020 | 1.91 Million CAD | 24522.6% |
| 2019 | 7765.00 CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 477.74 Thousand CAD | -50.66% |
| 2024 Q2 | 668.84 Thousand CAD | -57.88% |
| 2024 Q1 | 1.58 Million CAD | -55.05% |
| 2024 Q3 | 968.28 Thousand CAD | 44.77% |
| 2023 Q1 | 300.7 Thousand CAD | -58.22% |
| 2023 FY | 3.53 Million CAD | 390.88% |
| 2023 Q4 | 3.53 Million CAD | 12.19% |
| 2023 Q3 | 3.14 Million CAD | 605.18% |
| 2023 Q2 | 446.54 Thousand CAD | 48.5% |
| 2022 Q4 | 719.66 Thousand CAD | -60.6% |
| 2022 FY | 719.66 Thousand CAD | -87.17% |
| 2022 Q3 | 1.82 Million CAD | -42.98% |
| 2022 Q2 | 3.2 Million CAD | -34.21% |
| 2022 Q1 | 4.86 Million CAD | -13.2% |
| 2021 Q1 | 2.46 Million CAD | 29.13% |
| 2021 FY | 5.6 Million CAD | 193.38% |
| 2021 Q4 | 5.6 Million CAD | -16.96% |
| 2021 Q3 | 6.75 Million CAD | -5.76% |
| 2021 Q2 | 7.16 Million CAD | 190.32% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q4 | 1.91 Million CAD | 0.0% |
| 2020 FY | 1.91 Million CAD | 24522.6% |
| 2019 FY | 7765.00 CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.77% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 93.383% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.554% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 95.473% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.633% |
| Mesoblast Limited | 667.9 Million USD | 99.928% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -560.191% |
| Genus plc | 1.02 Billion USD | 99.954% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 64.829% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 4.267% |
| Marizyme, Inc. | 22.01 Million USD | 97.83% |
| ContraFect Corporation | 20.67 Million USD | 97.69% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 23.804% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -22.384% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -25.007% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 66.639% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 88.477% |
| MultiCell Technologies, Inc. | 126.22 USD | -378403.407% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 49.159% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.628% |
| EV Biologics, Inc. | 431.71 Thousand USD | -10.663% |
| Q BioMed Inc. | 3.51 Million USD | 86.41% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.642% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 38.007% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -82.851% |
| Biomind Labs Inc. | 73.81 Thousand USD | -547.187% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.897% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.408% |
| Skye Bioscience, Inc. | 11.94 Million USD | 95.999% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 85.58% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 82.604% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 75.603% |
| IMV Inc. | 31.33 Million USD | 98.475% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 30.508% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 81.648% |
| GB Sciences, Inc. | 103.44 Thousand USD | -361.85% |
| Alpha Cognition Inc. | 2.45 Million USD | 80.517% |
| HST Global, Inc. | 1526.00 USD | -31207.143% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Halberd Corporation | 10.13 Thousand USD | -4615.694% |
| Enzolytics Inc. | 361.7 Million USD | 99.868% |
| Resverlogix Corp. | 8.11 Million USD | 94.113% |
| Affymax, Inc. | 7.44 Million USD | 93.581% |
| SYBLEU INC | 330.46 Thousand USD | -44.567% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 74.559% |
| argenx SE | 4.54 Billion USD | 99.989% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.29% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.998% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1997.129% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 94.662% |
| AVAX Technologies, Inc. | 7.37 Million USD | 93.524% |
| Zenith Capital Corp. | 7410.00 USD | -6347.328% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.986% |
| Ember Therapeutics, Inc. | 184.00 USD | -259545.109% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -48.458% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -82.79% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.893% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 67.026% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 84.207% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.093% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 48.516% |
| BioStem Technologies, Inc. | 14.56 Million USD | 96.719% |
| ONE Bio Corp. | 70.08 Million USD | 99.318% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -736.773% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -20581.688% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 51.643% |
| Agentix Corp. | 261.39 Thousand USD | -82.77% |
| LadRx Corporation | 2.3 Million USD | 79.299% |
| Cell Source, Inc. | 195.17 Thousand USD | -144.784% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 0.585% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -35.103% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -35.103% |
| NovAccess Global Inc. | 62.24 Thousand USD | -667.49% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 25.312% |
| Itoco Inc. | 1.4 Million USD | 65.877% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -399.438% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -350.705% |
| Kadimastem Ltd | 2.3 Million USD | 79.265% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -525.7% |
| CytoDyn Inc. | 11.13 Million USD | 95.71% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -234.154% |
| Mobile Lads Corp. | 52.00 USD | -918644.231% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2571.963% |
| Qrons Inc. | 420.00 USD | -113649.286% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -23.939% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 13.47% |
| Rebus Holdings, Inc. | 5000.00 USD | -9454.94% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -16.688% |
| International Stem Cell Corporation | 5.39 Million USD | 91.136% |
| Bioxytran, Inc. | 137.63 Thousand USD | -247.104% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 96.815% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.118% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -504.743% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 44.749% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 93.644% |
| Neutra Corp. | 2851.00 USD | -16657.173% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.526% |
| PureTech Health plc | 693.97 Million USD | 99.931% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 94.081% |
| IXICO plc | 15.84 Million USD | 96.985% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 94.232% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.538% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.857% |